Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.

 Thermo Fisher Scientific Inc. and the University of California, San Francisco will accelerate advanced cell therapies for difficult-to-treat conditions from a newly opened cGMP manufacturing facility.

Predictive Oncology Inc. together with Cancer Research Horizons, announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.

Owlstone Medical has announced that it has entered into a Research Agreement with Bicycle Therapeutics plc.

OGT announces that IVDR certification has been granted for eight CytoCell® fluorescence in situ hybridization (FISH) probes important for patient management in hematological cancers and prenatal conditions.

SonALAsense has announced that the first cohort in Sonodynamic Therapy (SDT)-202 was fully enrolled.

Personalis, Inc. has announced it will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

TransCure bioServices has developed cell line-derived xenograft mouse models that will change how researchers tackle the preclinical studies of cancer therapies to treat acute myeloid leukemia.

Voltron Therapeutics, Inc. has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

Akamis Bio has announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy to include a clinical collaboration with the Cancer Research Institute that will focus on advancing novel treatments for pancreatic cancer.